Track topics on Twitter Track topics that are important to you
Charles C. Wykoff
NEW ORLEANS — At 6 months, the HULK phase 1/2 trial demonstrated visual acuity benefit for all patients enrolled and a greater benefit for treatment-naïve eyes, Charles C. Wykoff, MD, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.
The objective of the trial was to evaluate the safety and efficacy of 4 mg Zuprata (triamcinolone acetonide injectable suspension, Clearside Biomedical) administered to the suprachoroidal space alone or in conjunction with 2 mg intravitreal Eylea (aflibercept, Regeneron) for diabetic macular edema.
Original Article: Visual acuity gains seen in HULK trialNEXT ARTICLE
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...